2012, Number 2
<< Back Next >>
Revista Cubana de Anestesiología y Reanimación 2012; 11 (2)
Cerebral natriuretic peptide and its pro-hormone as predictor of cardiovascular risk in non-cardiac surgery
Correa PJM
Language: Spanish
References: 42
Page:
PDF size: 46.87 Kb.
ABSTRACT
Introduction: The prevalence of the cardiovascular disease increases with age and the major non-cardiac surgery is associated with a high risk of early cardiovascular complications.
Objectives: To make an updating on the usefulness of the cerebral natriuretic peptide and the terminal fraction of its pro-hormone as a predictor of the cardiovascular risk in non-cardiac surgery.
Development: Traditionally is has been proposed that the imbalance among factors modifying the contribution/consumption of 02 at myocardial level, as well as the hemoglobin levels and the plate vulnerability are the factor with a great incidence in the appearance of perioperative cardiac complications. In past years, the usefulness of both peptides in diagnosis and prognosis of patients presenting with a cardiac failure, have lead to a great interest on its potential use as prognosis in the appearance of postoperative cardiovascular complications.
Complications: Both natriuretic peptides are a significant tool in prediction or cardiovascular morbility and mortality in non-cardiac surgery and also are independent cardiovascular risk factors with a high sensitivity and specificity.
REFERENCES
Anuario Estadístico de Salud. 2010. Revisado Abril 2011. Encontrado en www.infomed.sld.cu
Fleisher LA, Eagle KA. Clinical practice: lowering cardiac risk in noncardiac surgery. N Engl J Med 2001; 345:1677-82.
Lopez-Jimenez F, Goldman L, Sacks DB, Thomas EJ, Johnson PA, Cook EF, Lee TH. Prognostic value of cardiac troponin T after noncardiac surgery: 6-month follow-up data. J Am Coll Cardiol 1997; 29: 1241-1245.
Landesberg G, Shatz V, Akopnik I, Wolf YG, Mayer M, Berlatzky Y, Weissman C, Mosseri M. Association of cardiac troponin, CK-MB, and postoperative myocardial ischemia with long-term survival after major vascular surgery. J Am Coll Cardiol 2003; 42:1547-1554.
Fleisher LA, Beckman JA, Brown KA, et al. ACC / AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007; 116: 1971-96.
Falcone RA, Nass C, Jermyn R, et al. The value of preoperative pharmacologic stress testing before vascular surgery using ACC / AHA guidelines: a prospective, randomized trial. Journal of Cardiothoracic and Vascular Anesthesia 2003; 17: 694_8.
McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. New England Journal of Medicine 2004; 351: 2795_804.
Wiesbauer F, Schlager O, Domanovits H, et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity: a systematic review and meta-analysis. Anesthesia and Analgesia 2007; 104: 27-41.
Freeman WK, Gibbons RJ. Perioperative cardiovascular assessment of patients undergoing noncardiac surgery. Mayo Clin Proc. 2009; 84(1):79-90.
Goldman L. Cardiac risks and complications of noncardiac surgery. Ann Intern Med 1983; 98:504-13.
Ridley S. Cardiac scoring systems -what is their value? Anaesthesia 2003; 58: 985-91.
Kertai MD, Boersma E, Bax JJ, et al. A meta-analysis comparing the prognostic accuracy of six diagnostic tests for predicting perioperative cardiac risk in patients undergoing major vascular surgery. Heart 2003; 89: 1327-34.
Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989; 261: 884_888.
Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332:78-81.
Hystad ME, Geiran OR, Attramadal H, et al. Regional cardiac expression and concentration of natriuretic peptides in patients with severe chronic heart failure. Acta Physiologica Scandinavica 2001; 171: 395-403.
Tsuruda T, Boerrigter G, Huntley BK, et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circulation Research 2002; 91: 1127-34.
Goetze JP, Gore A, Moller CH, Steinbruchel DA, Rehfeld JF, Nielsen LB. Acute myocardial hypoxia increases BNP gene expression. The FASEB Journal 2004; 18: 1928-30.
Hall C. Essential biochemistry and physiology of (NT-pro) BNP. European Journal of Heart Failure 2004; 6: 257-60.
Sawada Y, Suda M, Yokoyama H, et al. Stretch-induced hypertrophic growth of cardiocytes and processing of braintype natriuretic peptide are controlled by proprotein-processing endoprotease furin. J Biol Chem 1997; 272:20 545-20 554.
Qi W, Kjekshus J, Hall C. Differential responses of plasma atrial and brain natriuretic peptidesto acute alteration in atrial pressure in pigs. Scand J Clin Lab Invest 2000; 60:55 -63.
Levin ER, Gardner DG, Samson WK. Natriuretic peptides. New England Journal of Medicine 1998; 339: 321-8.
Koller KJ, Goeddel DV. Molecular biology of the natriuretic peptides and their receptors. Circulation 1992; 86:1081-8.
Maack T, Suzuki M, Almeida FA, et al. Physiological role of silent receptors of atrial natriuretic factor. Science 1987; 238: 675-8.
Gardner DG, Chen S, Glenn DJ, Grigsby CL. Molecular biology of the natriuretic peptide system: implications for physiology and hypertension. Hypertension 2007; 49: 419-26.
Nishikimi T, Maeda N, Matsuoka H. The role of natriuretic peptides in cardioprotection. Cardiovascular Research 2006; 69: 318-28.
Smith MW, Espiner EA, Yandle TG, Charles CJ, Richards AM. Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J Endocrinol 2000; 167:239-46.
Richards M, Nicholls MG, Espiner EA, et al. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. Journal of the American College of Cardiology 2006; 47: 52-60.
Chang AY, Abdullah SM, Jain T, et al. Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. Journal of the American College of Cardiology 2007; 49: 109_16.
Sarzani R, Dessi-Fulgheri P, Paci VM, Espinosa E, Rappelli A. Expression of natriuretic peptide receptors in human adipose and other tissues. Journal of Endocrinological Investigation 1996; 19: 581-5.
Dessi-Fulgheri P, Sarzani R, Tamburrini P, et al. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. Journal of Hypertension 1997; 15: 1695-9.
McCullough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides.-Reviews in Cardiovascular Medicine 2003; 4 (Suppl. 4): S13-9.
Ng LL, Loke IW, Davies JE, et al. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides. Journal of the American College of Cardiology 2005; 45: 1043-50.
Austin WJ, Bhalla V, Hernandez-Arce I, et al. Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. American Journal of Clinical Pathology 2006; 126: 506-12.
van Kimmenade RR, Pinto YM, Januzzi JL Jr. Importance and interpretation of intermediate (gray zone) aminoterminal pro-B-type natriuretic peptide concentrations.The American Journal of Cardiology 2008; 101: 39-42.
Dernellis J, Panaretou M. Assessment of cardiac risk before non-cardiac surgery: brain natriuretic peptide in 1590 patients. Heart 2006; 92: 1645-50.
Sung Eun Kim, Dae-Gyun Park, Jun Hee Lee, Kyoo Rok Han, Dong Jin Oh. Utility of B-Type Natriuretic Peptide for predicting perioperative cardiovascular events in patients withouth History of cardiovascular disease undergoing major non-cardiac surgery. Korean Circ J 2011; 41:11-15.
Cuthbertson BH, Amiri AR, Croal BL, Rajagopalan S, Alozairi O, Brittenden J, Hillis GS. Utility of B-type natriuretic peptide in predicting perioperative cardiac events in patients undergoing major non-cardiac surgery. British Journal of Anaesthesia 2007; 99 (2): 170_6.
Cuthbertson BH, Amiri AR, Croal BL, Rajagopalan S, Alozairi O, Brittenden J, Hillis GS. Utility of B-Type Natriuretic Peptide in predicting medium-term mortality in patients undergoing major non-cardiac surgery. Am J Cardiol 2007; 100:1310-1313.
Berry C; Kingsmore D, Gibson S, Hole D, Morton JJ, Byrne D, Dargie HJ. Predictive value of plasma brain natriuretic peptide for cardiac outcome after vascular surgery. -Heart 2006; 92:401-402.
Schutt RC, Cevik C, Phy MP. Plasma N-Terminal prohormone brain natriuretic peptide as a marker for postoperative cardiac events in high-risk patients Undergoing noncardiac surgery. Am J Cardiol 2009; 104:137-140.
Goei D, van Kuijk JP, Flu Wj, Hoeks SN, Chonchol M, Verhagen HJM, Bax JJ, Poldermans D. Usesfulnes of repeated N-terminal Pro-B-type natriuretic peptide measurements as incremental predictor for long-term cardiovascular outcome after vascular surgery. Am J Cardiol 2011; 107:609_614.
Yeh HM, Lau HP, Lin JM, Sun WZ, Wang MJ, Lai LP. Preoperative plasma N-terminal pro-brain natriuretic peptide as a marker of cardiac risk in patients undergoing elective non-cardiac surgery. British Journal of Surgery 2005; 92: 1041-1045.